Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

BACKGROUND: In light of the increased risk of progressive multifocal encephalopathy (PML) development under long-term treatment with the monoclonal antibody natalizumab which is approved for treatment of active relapsing remitting multiple sclerosis (RRMS), there is a clear need for alternative trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Klotz, Luisa, Grützke, Berit, Eveslage, Maria, Deppe, Michael, Gross, Catharina C., Kirstein, Lucienne, Posevitz-Fejfar, Anita, Schneider-Hohendorf, Tilman, Schwab, Nicholas, Meuth, Sven G., Wiendl, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477482/
https://www.ncbi.nlm.nih.gov/pubmed/26099927
http://dx.doi.org/10.1186/s12883-015-0354-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477482/
https://www.ncbi.nlm.nih.gov/pubmed/26099927
http://dx.doi.org/10.1186/s12883-015-0354-9

Ejemplares similares